Depomedroxyprogesterone acetate for hot flashes

Debra Barton, Charles Lawrence Loprinzi, Susan Quella, Jeff A Sloan, Sandhya Pruthi, Paul Novotny

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

To evaluate the efficacy of a long-acting preparation of medroxyprogesterone acetate for hot flash management, 3 men receiving androgen ablation therapy for prostate cancer and 15 women with a history of breast cancer were treated as part of clinical practice with three biweekly intramuscular injections of 500 mg depomedroxyprogesterone. A review of hot flash diaries and patient charts were completed to evaluate the effectiveness and tolerability of these injections for managing hot flashes. Treatment was associated with an approximate 90% decrease in hot flashes (95% CI 82-97%). Daily hot flash frequency decreased from a mean of 10.9 on the first day of treatment (95% CI 8.0-13.8 hot flashes per day) to a mean of 1.1 hot flashes 6 weeks later (95% CI 0.5-1.8 hot flashes) and to a mean of 0.7 hot flashes 12 weeks following therapy initiation (95% CI 0.1-1.2). Improvement in the hot flashes remained for months after discontinuing the injections in many patients. Reported side effects were minimal. This experience suggests that treatment with depomedroxyprogesterone may be an effective and well-tolerated option for the treatment of hot flashes.

Original languageEnglish (US)
Pages (from-to)603-607
Number of pages5
JournalJournal of Pain and Symptom Management
Volume24
Issue number6
DOIs
StatePublished - Dec 1 2002

Fingerprint

Hot Flashes
Acetates
Therapeutics
Medroxyprogesterone Acetate
Injections
Intramuscular Injections
Androgens
Prostatic Neoplasms

Keywords

  • Breast cancer survivors
  • Depomedroxyprogesterone acetate
  • Hot flashes
  • Menopause

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Clinical Neurology
  • Neurology
  • Nursing(all)

Cite this

Depomedroxyprogesterone acetate for hot flashes. / Barton, Debra; Loprinzi, Charles Lawrence; Quella, Susan; Sloan, Jeff A; Pruthi, Sandhya; Novotny, Paul.

In: Journal of Pain and Symptom Management, Vol. 24, No. 6, 01.12.2002, p. 603-607.

Research output: Contribution to journalArticle

@article{5d809bc16dca4872a7176b661466ae63,
title = "Depomedroxyprogesterone acetate for hot flashes",
abstract = "To evaluate the efficacy of a long-acting preparation of medroxyprogesterone acetate for hot flash management, 3 men receiving androgen ablation therapy for prostate cancer and 15 women with a history of breast cancer were treated as part of clinical practice with three biweekly intramuscular injections of 500 mg depomedroxyprogesterone. A review of hot flash diaries and patient charts were completed to evaluate the effectiveness and tolerability of these injections for managing hot flashes. Treatment was associated with an approximate 90{\%} decrease in hot flashes (95{\%} CI 82-97{\%}). Daily hot flash frequency decreased from a mean of 10.9 on the first day of treatment (95{\%} CI 8.0-13.8 hot flashes per day) to a mean of 1.1 hot flashes 6 weeks later (95{\%} CI 0.5-1.8 hot flashes) and to a mean of 0.7 hot flashes 12 weeks following therapy initiation (95{\%} CI 0.1-1.2). Improvement in the hot flashes remained for months after discontinuing the injections in many patients. Reported side effects were minimal. This experience suggests that treatment with depomedroxyprogesterone may be an effective and well-tolerated option for the treatment of hot flashes.",
keywords = "Breast cancer survivors, Depomedroxyprogesterone acetate, Hot flashes, Menopause",
author = "Debra Barton and Loprinzi, {Charles Lawrence} and Susan Quella and Sloan, {Jeff A} and Sandhya Pruthi and Paul Novotny",
year = "2002",
month = "12",
day = "1",
doi = "10.1016/S0885-3924(02)00525-0",
language = "English (US)",
volume = "24",
pages = "603--607",
journal = "Journal of Pain and Symptom Management",
issn = "0885-3924",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Depomedroxyprogesterone acetate for hot flashes

AU - Barton, Debra

AU - Loprinzi, Charles Lawrence

AU - Quella, Susan

AU - Sloan, Jeff A

AU - Pruthi, Sandhya

AU - Novotny, Paul

PY - 2002/12/1

Y1 - 2002/12/1

N2 - To evaluate the efficacy of a long-acting preparation of medroxyprogesterone acetate for hot flash management, 3 men receiving androgen ablation therapy for prostate cancer and 15 women with a history of breast cancer were treated as part of clinical practice with three biweekly intramuscular injections of 500 mg depomedroxyprogesterone. A review of hot flash diaries and patient charts were completed to evaluate the effectiveness and tolerability of these injections for managing hot flashes. Treatment was associated with an approximate 90% decrease in hot flashes (95% CI 82-97%). Daily hot flash frequency decreased from a mean of 10.9 on the first day of treatment (95% CI 8.0-13.8 hot flashes per day) to a mean of 1.1 hot flashes 6 weeks later (95% CI 0.5-1.8 hot flashes) and to a mean of 0.7 hot flashes 12 weeks following therapy initiation (95% CI 0.1-1.2). Improvement in the hot flashes remained for months after discontinuing the injections in many patients. Reported side effects were minimal. This experience suggests that treatment with depomedroxyprogesterone may be an effective and well-tolerated option for the treatment of hot flashes.

AB - To evaluate the efficacy of a long-acting preparation of medroxyprogesterone acetate for hot flash management, 3 men receiving androgen ablation therapy for prostate cancer and 15 women with a history of breast cancer were treated as part of clinical practice with three biweekly intramuscular injections of 500 mg depomedroxyprogesterone. A review of hot flash diaries and patient charts were completed to evaluate the effectiveness and tolerability of these injections for managing hot flashes. Treatment was associated with an approximate 90% decrease in hot flashes (95% CI 82-97%). Daily hot flash frequency decreased from a mean of 10.9 on the first day of treatment (95% CI 8.0-13.8 hot flashes per day) to a mean of 1.1 hot flashes 6 weeks later (95% CI 0.5-1.8 hot flashes) and to a mean of 0.7 hot flashes 12 weeks following therapy initiation (95% CI 0.1-1.2). Improvement in the hot flashes remained for months after discontinuing the injections in many patients. Reported side effects were minimal. This experience suggests that treatment with depomedroxyprogesterone may be an effective and well-tolerated option for the treatment of hot flashes.

KW - Breast cancer survivors

KW - Depomedroxyprogesterone acetate

KW - Hot flashes

KW - Menopause

UR - http://www.scopus.com/inward/record.url?scp=0036962481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036962481&partnerID=8YFLogxK

U2 - 10.1016/S0885-3924(02)00525-0

DO - 10.1016/S0885-3924(02)00525-0

M3 - Article

VL - 24

SP - 603

EP - 607

JO - Journal of Pain and Symptom Management

JF - Journal of Pain and Symptom Management

SN - 0885-3924

IS - 6

ER -